C-J Advisory’s Global Blood Therapeutics, Inc. GBT Stock Holding History

C-J Advisory’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-60	Closed	-$3K	–	160
2019 Q3	$3K	Hold	60	–	–	﹤0.01%	163
2019 Q2	$3K	Hold	60	–	–	﹤0.01%	166
2019 Q1	$3K	Hold	60	–	–	﹤0.01%	180
2018 Q4	$2K	Hold	60	–	–	﹤0.01%	154
2018 Q3	$2K	Hold	60	–	–	﹤0.01%	167
2018 Q2	$3K	Buy	+60	New	+$2.73K	﹤0.01%	160

Other funds holding GBT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

C-J Advisory's GBT Position: Q4 2019 in Review

C-J Advisory sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2019, closing a stake of 60 shares — an estimated $3K sold.

C-J Advisory first reported a position in GBT in Q2 2018 and held it in 6 quarters. The position peaked at $3K in Q3 2019. 234 funds tracked by Wall St. Rank hold GBT as of Q4 2019.

C-J Advisory reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
C-J Advisory sold 60 Global Blood Therapeutics, Inc. shares in Q4 2019, an estimated $3K.
C-J Advisory first reported a position in Global Blood Therapeutics, Inc. in Q2 2018 and held it in 6 quarters.
C-J Advisory's Global Blood Therapeutics, Inc. position peaked at $3K in Q3 2019.
234 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2019.

Based on C-J Advisory's 13F filing for Q4 2019, filed 10 Feb 2020.